Sugi Predict

Sugi Predict / Compounds / SCHEMBL509300

SCHEMBL509300

SCHEMBL509300

CC(C)(C)OC(=O)NC1CCC2(CC1)CO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.48
▸ GAA P10253 2/20 0.47
▸ CTSK P43235 2/20 0.44
▸ EPHX1 P07099 1/20 0.42
▸ KDM1A O60341 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ JAK2 O60674 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ CKS1B P61024 1/20 0.39
▸ SKP1 P63208 1/20 0.39
▸ SKP2 Q13309 1/20 0.39
▸ CYP2C9 P11712 1/20 0.38
▸ HSD11B1 P28845 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12528056 1.00 BTK (0.48) BTKGAACTSKEPHX1KDM1A
SCHEMBL24340475 0.89 BTK (0.47) BTKGAACTSKEPHX1KDM1A
SCHEMBL28950899 0.89 BTK (0.47) BTKGAACTSKEPHX1KDM1A
SCHEMBL570579 0.83 GAA (0.49) BTKGAACTSKEPHX1KDM1A
SCHEMBL5263809 0.83 BTK (0.47) BTKGAACTSKEPHX1KDM1A
SCHEMBL10239268 0.82 BTK (0.50) BTKGAACTSKEPHX1KDM1A
SCHEMBL15294478 0.82 BTK (0.50) BTKGAACTSKEPHX1KDM1A
SCHEMBL31402079 0.82 BTK (0.50) BTKGAACTSKEPHX1KDM1A
SCHEMBL24424581 0.82 BTK (0.43) BTKGAACTSKEPHX1KDM1A
SCHEMBL10239202 0.82 BTK (0.50) BTKGAACTSKEPHX1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4613748-A1 IRAK4 DEGRADATION AGENT AND USE THEREOF Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) 2025-09-10 — — EP disclosed
US-20250188069-A1 COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA PIN THERAPEUTICS, INC. (KR) 2025-06-12 — — US disclosed
EP-4558495-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 Bristol-Myers Squibb Company (US) 2025-05-28 — — EP disclosed
EP-4543868-A1 COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA Pin Therapeutics, Inc. (KR) 2025-04-30 — — EP disclosed
CN-119894895-A IRAK4 degradation agent and application thereof 领泰生物医药(绍兴)有限公司 2025-04-25 — — CN disclosed
WO-2025067111-A1 MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION 苏州必扬医药科技有限公司 2025-04-03 — — WO disclosed
US-20240368194-A1 IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-11-07 — — US disclosed
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 — — EP disclosed
EP-4393922-A1 IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-07-03 — — EP disclosed
US-20240173419-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-05-30 — — US disclosed
US-8071643-B2 Pleuromutilin derivatives for the treatment of diseases mediated by microbes NABRIVA THERAPEUTICS AG (AT) 2011-12-06 — — US disclosed
EP-2380874-A2 Pleuromutilin derivatives for the treatment of diseases mediated by microbes Nabriva Therapeutics AG (AT) 2011-10-26 — — EP disclosed
US-8039503-B2 Lapachone compounds and methods of use thereof ARQULE, INC. (US) 2011-10-18 — — US disclosed
EP-2137143-B1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES NABRIVA THERAPEUTICS AG (AT) 2011-09-07 — — EP disclosed
US-20110105470-A1 Novel Lapachone Compounds And Methods of Use Thereof ARQULE, INC. (US) 2011-05-05 — — US disclosed
US-7902354-B2 Lapachone compounds and methods of use thereof ARQULE, INC. (US) 2011-03-08 — — US disclosed
US-20100035987-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES NABRIVA THERAPEUTICS AG (AT) 2010-02-11 — — US disclosed
US-20090105166-A1 Novel lapachone compounds and methods of use thereof ARQULE, INC. 2009-04-23 — — US disclosed
EP-2035435-A1 NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE, INC. (US) 2009-03-18 — — EP disclosed
WO-2007139569-A1 NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE, INC. (US) 2007-12-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105470-A1 Novel Lapachone Compounds And Methods of Use Thereof BAD, NQO1, CASP3 BTK 4560/4885GAA 2960/4885CTSK 1167/4885
US-20240368194-A1 IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 BTK 239/4885GAA 2894/4885CTSK 2526/4885
US-20100035987-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, FABP6, ALPI BTK 3006/4885GAA 129/4885CTSK 2731/4885
US-20250188069-A1 COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA CSNK1A1, CSNK1G1, CSNK2A1 BTK 2662/4885GAA 84/4885CTSK 28/4885
US-20240173419-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 BTK 738/4885GAA 2132/4885CTSK 1245/4885
US-20090105166-A1 Novel lapachone compounds and methods of use thereof BAD, NQO1, CASP3 BTK 4560/4885GAA 2960/4885CTSK 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.